Maxime Fontanilles

Dr. Maxime Fontanilles

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NONathalie OLYMPIOS
Nathalie OLYMPIOS
VGVianney GILARD
Vianney GILARD
MFMaxime Fontanilles
Maxime Fontanilles
FCFlorian Clatot
Florian Clatot
FFFrédéric Di Fiore
Frédéric Di Fiore
MFMaxime Fontanilles
Maxime Fontanilles
Glioblastoma, the most frequent and aggressive primary malignant tumor, often presents with alterations in the telomerase reverse transcriptase promoter. Telomerase is responsible for the maintenance of telomere length to avoid cell death. Telomere lengthening is required for cancer cell survival and has led to the investigation of telomerase activity as a potential mechanism that enables cancer growth. The aim of this systematic review is to provide an overview of the available data concerning TERT alterations and glioblastoma in terms of incidence, physiopathological understanding, and potential therapeutic implications.

1 June 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MFMaxime Fontanilles
Maxime Fontanilles
FMFlorent Marguet
Florent Marguet
EBElodie Bohers
Elodie Bohers
PVPierre-Julien VIAILLY
Pierre-Julien VIAILLY
SDSydney Dubois
Sydney Dubois
FJFabrice Jardin
Fabrice Jardin
Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma

Verified
Journal Article
Open access
PDF file
VGVianney GILARD
Vianney GILARD
ATAbdellah Tebani
Abdellah Tebani
Ivana DABAJIvana DABAJ
Ivana DABAJ
ALAnnie Laquerrière
Annie Laquerrière
MFMaxime Fontanilles
Maxime Fontanilles
SBSoumeya Bekri
Soumeya Bekri
Glioblastoma is the most common malignant brain tumor in adults. The current management relies on surgical resection and adjuvant radiotherapy and chemotherapy. Despite advances in our understanding of glioblastoma onset, we are still faced with an increased incidence, an altered quality of life and a poor prognosis, its relapse and a median overall survival of 15 months. For the past few years, the understanding of glioblastoma physiopathology has experienced an exponential acceleration and yielded significant insights and new treatments perspectives. In this review, through an original R-based literature analysis, we summarize the clinical presentation, current standards of care and outcomes in patients diagnosed with glioblastoma. We also present the recent advances and perspectives regarding pathophysiological bases as well as new therapeutic approaches such as cancer vaccination and personalized treatments.

4 November 2020 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
MFMaxime Fontanilles
Maxime Fontanilles
FMFlorent Marguet
Florent Marguet
LBLudivine Beaussire
Ludivine Beaussire
NMNicolas Magne
Nicolas Magne
LPLouis-Ferdinand Pépin
Louis-Ferdinand Pépin
FCFlorian Clatot
Florian Clatot
The clinical implications of plasmatic cell-free and tumor DNA (cfDNA and ctDNA) are challenging in glioblastoma. This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma (n = 3) patients treated with concomitant temozolomide and radiotherapy (RT-TMZ), followed by a TMZ maintenance phase. Plasma samples were collected at baseline, before RT-TMZ (pre-RT-TMZ) and at the end of adjuvant TMZ, or at the time of progression in cases of progressive disease (PD). The cfDNA concentration was measured with a fluorometric method, and ctDNA was detected using targeted droplet digital PCR. The main objectives were to analyze the associations between cfDNA and ctDNA measurements during the course of treatment with PD and survival. There was a significant decrease in median cfDNA concentration from baseline to pre-RT-TMZ—19.4 versus 9.7 ng/mL (p < 0.0001)—in the entire cohort. In patients with PD, a significant increase in cfDNA concentration from pre-RT-TMZ to time of PD was observed, from 9.7 versus 13.1 ng/mL (p = 0.037), respectively, while no difference was observed for nonprogressive patients. Neither the cfDNA concentration at baseline nor its kinetics correlated with survival. ctDNA was detected in 2 patients (3.8%) and only in gliosarcoma subtypes.Trial registration ClinicalTrial, NCT02617745. Registered 1 December 2015, https://clinicaltrials.gov/ct2/show/NCT02617745?term=glioplak&draw=2&rank=1.

9 March 2018 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
MFMaxime Fontanilles
Maxime Fontanilles
ADAlberto Duran-Peña
Alberto Duran-Peña
Ahmed IdbaihAhmed Idbaih
Ahmed Idbaih

12 October 2024 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
MFMaxime Fontanilles
Maxime Fontanilles
JHJean-David Heisbourg
Jean-David Heisbourg
ADArthur Daban
Arthur Daban
FFFrederic Di Fiore
Frederic Di Fiore
LPLouis-Ferdinand Pépin
Louis-Ferdinand Pépin
ATAbdellah Tebani
Abdellah Tebani
Monitoring tumor evolution and predicting survival using non-invasive liquid biopsy is an unmet need for glioblastoma patients. The era of proteomics and metabolomics blood analyzes, may help in this context. A case–control study was conducted. Patients were included in the GLIOPLAK trial (ClinicalTrials.gov Identifier: NCT02617745), a prospective bicentric study conducted between November 2015 and December 2022. Patients underwent biopsy alone and received radiotherapy and temozolomide. Blood samples were collected at three different time points: before and after concomitant radiochemotherapy, and at the time of tumor progression. Plasma samples from patients and controls were analyzed using metabolomics and proteomics, generating 371 omics features. Descriptive, differential, and predictive analyses were performed to assess the relationship between plasma omics feature levels and patient outcome. Diagnostic performance and longitudinal variations were also analyzed. The study included 67 subjects (34 patients and 33 controls). A significant differential expression of metabolites and proteins between patients and controls was observed. Predictive models using omics features showed high accuracy in distinguishing patients from controls. Longitudinal analysis revealed temporal variations in a few omics features including CD22, CXCL13, EGF, IL6, GZMH, KLK4, and TNFRSP6B. Survival analysis identified 77 omics features significantly associated with OS, with ERBB2 and ITGAV consistently linked to OS at all timepoints. Pathway analysis revealed dynamic oncogenic pathways involved in glioblastoma progression. This study provides insights into the potential of plasma omics features as biomarkers for glioblastoma diagnosis, progression and overall survival. Clinical implication should now be explored in dedicated prospective trials.